Table 1 Baseline patient characteristics
Characteristic | Total n = 62 | COVID-19 n = 30 | Non-COVID-19 n = 32 |
|---|---|---|---|
Male sex (number, %) | 37 (60%) | 20 (67%) | 17 (53%) |
Age (years) | 66 (59–72) | 66 (59–73) | 67 (57–71) |
Length (cm)a | 173 (169–178) | 173 (169–179) | 173 (169–178) |
Weight (kg) | 85 (70–105) | 91 (76–109) | 83 (68–94) |
BMI (kg/m2)a | 27.8 (24.3–32.0) | 30.0 (25.6–35.6) | 26.6 (22.2–29.7) |
APACHE IV score | 72 (59–90) | 65 (56–74) | 89 (69–103) |
Diagnosis (number, %) | |||
Pulmonary | 41 (66%) | 11 (35%) | |
of which COVID-19 | 30 (48%) | 30 (100%) | |
Cardiovascular | 7 (11%) | 7 (22%) | |
Renal | 3 (4.8%) | 3 (9%) | |
Gastro-intestinal | 2 (3.2%) | 2 (6%) | |
Other | 9 (15%) | 9 (28%) | |
Comorbidity (number, %) | |||
Hypertension | 29 (47%) | 14 (47%) | 15 (47%) |
MI/other cardiac diseases | 19 (31%) | 12 (40%) | 7 (22%) |
Diabetes Mellitus | 16 (26%) | 5 (17%) | 11 (34%) |
COPD/Asthma | 15 (24%) | 5 (17%) | 10 (31%) |
Morbid obesity | 6 (9.7%) | 4 (13%) | 2 (6%) |
CVA | 5 (8.1%) | 1 (3%) | 4 (13%) |
Chronic renal failure | 4 (6.5%) | 2 (7%) | 2 (6%) |
Malignancy | 3 (4.8%) | 1 (3%) | 2 (6%) |
None | 3 (4.8%) | 2 (7%) | 1 (3%) |
VTE (DVT/PE) | 1 (1.6%) | - | 1 (3%) |
Other | 52 (84%) | 23 (77%) | 29 (91%) |
Laboratory values at baselineb | |||
Creatinine (µmol/L) | 76 (60–98) | 65 (52–90) | 87 (62–129) |
Creatinine clearance (eGFR CKD-EPI, ml/min/1.73m2) | 88 (64–98) | 92 (70–102) | 78 (43–95) |
CRP (mg/L) | 73 (25–193) | 83 (53–167) | 39 (4-277) |
Hb (g/dL) | 13.54 (11.60-14.18) | 13.05 (11.28–14.02) | 13.70 (11.76–14.99) |
Platelet count (x109/L) | 260 (181–344) | 251 (178–372) | 266 (181–339) |
D-dimerc (µg/L) | - | 2540 (928–5745) | - |